CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 53488-53691 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T72869","span":{"begin":0,"end":203},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The consistently positive impact of omalizumab on ARQL outcomes during the clinical trial program provides evidence of its value as an adjunct therapy in patients with moderate-to-severe allergic asthma."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T36","span":{"begin":0,"end":203},"obj":"Sentence"}],"text":"The consistently positive impact of omalizumab on ARQL outcomes during the clinical trial program provides evidence of its value as an adjunct therapy in patients with moderate-to-severe allergic asthma."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T468","span":{"begin":187,"end":202},"obj":"Disease"},{"id":"T469","span":{"begin":187,"end":195},"obj":"Disease"},{"id":"T470","span":{"begin":196,"end":202},"obj":"Disease"}],"attributes":[{"id":"A468","pred":"mondo_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/MONDO_0004784"},{"id":"A469","pred":"mondo_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A470","pred":"mondo_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"The consistently positive impact of omalizumab on ARQL outcomes during the clinical trial program provides evidence of its value as an adjunct therapy in patients with moderate-to-severe allergic asthma."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T246","span":{"begin":196,"end":202},"obj":"Phenotype"}],"attributes":[{"id":"A246","pred":"hp_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"The consistently positive impact of omalizumab on ARQL outcomes during the clinical trial program provides evidence of its value as an adjunct therapy in patients with moderate-to-severe allergic asthma."}